老熟女另类,老熟女乱伦,老熟女乱婬一区二区,老熟女毛茸茸,老熟女毛茸茸黑森森,老熟女毛茸茸浓毛,老熟女网,老熟女网站。

CN / EN

News

Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial

Release time: 2023-04-19 Article source: 特科羅

CHENGDU – April 17, 2023 (XYZ Newswire) Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has begun dosing patients in its Androgenetic Alopecia (AGA) Phase 2 clinical trial of topical TDM-105795 solution. This clinical trial in the AGA program includes 16 weeks dosing of two different active formulation strengths and placebo in a study entitled, “A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects with Androgenetic Alopecia”. Study objectives are to evaluate efficacy, safety and pharmacokinetics of topical TDM-105795. Approximately 12 U.S. clinical sites are currently participating in this study under an open IND with FDA.

Arthur P. Bertolino, MD, PhD, MBA, Chief Medical Officer at Technoderma Medicines commented, “We  expect the current study design to support Proof-of -Concept regarding hair growth efficacy and to guide choice of formulation strength(s) appropriate for late stage clinical development. Observation of meaningful quantitative data regarding hair counts and global photographic assessments of hair growth will enable us to anchor the program .”

“Transition into a Phase 2 study with this lead clinical program is a major milestone for the Company. We now have assets in multiple phases of clinical development and anticipate bringing another pipeline product into clinical testing later this year,” said Zengquan Wang, Chief Executive Officer at Technoderma Medicines. “We have demonstrated that the Company can sustainably produce a robust portfolio of dermatology drug candidates.”

About TDM-105795

TDM105795 is a small molecule drug candidate being developed as a topical drug for treatment of Androgenetic Alopecia. As a potent thyromimetic, it may offer significant advantages regarding efficacy and safety compared to existing treatments. Preclinical assessment of TDM-105795 indicates that it has poor systemic absorption following topical application and a short elimination half-life, features well-suited to avoid unwanted systemic effects. Moreover, in vivo efficacy studies in C3H mice showed that TDM-105795 was able to potently stimulate hair growth in a dose-dependent manner when applied topically. This is likely because TDM-105795 is able to activate dormant hair follicle stem cells and induce anagen (growth phase) in telogen (resting phase) hair follicles when binding to hair follicle cell target receptor proteins. Testing in rats and minipigs demonstrated favorable toxicology and toxicokinetic profiles.  Phase 1 clinical testing showed it to have a favorable safety profile and to be well-tolerated.

About Androgenetic Alopecia (AGA)

Androgenetic Alopecia (AGA), also called male or female pattern baldness, is the most common hair loss condition affecting both men and women, with a higher incidence in men. While more than half of adult males suffer from AGA, this rate increases to 80% in men at age 50 and above. Male AGA is characterized by receding hairline and baldness on the top and front of the head. Female AGA is usually manifested as hair density thinning on the top and crown of the head. As a degenerative disorder with etiology largely unknown, genetic, psychological and mental, endocrinologic and metabolic factors may play a role. The pathogenesis underlying AGA has been linked to hyperactivation of androgen receptors in hair follicle cells, rendering resting hair follicles unable to re-enter the growth phase and undergoing miniaturization.

About Technoderma Medicines

Technoderma Medicines, Inc. is a privately held clinical stage biopharmaceutical company. The Company was originally located in Jiaxing Xiuzhou Biomedicine Guoqian Park, China, and recently relocated to Chengdu Biomed Town, Chengdu, Sichuan Province, China. Its current core programs focus on development of innovative therapies for Androgenetic Alopecia, Atopic Dermatitis, Psoriasis and Lupus Erythematosus. Its "first-in-class" small molecule thyromimetic drug candidate TDM-105795 for Androgenetic Alopecia is currently in Phase 2a clinical testing. Technoderma’s novel JAK1/TYK2 inhibitor TDM-180935 for Atopic Dermatitis is now in Phase 1 clinical testing. The pipeline targets dermatologic indications.

主站蜘蛛池模板: 日本成a人片在线观看影院 日本成本人片视频免费 | 亚洲中文字幕永久免费在线观看 | 亚洲精品成人女人 | 国产精品午夜福利影院在线观看 | 91久久偷偷做嫩草影院 | 国产成人av一区二区三区不卡 | 国产一区二区三区中文在线 | 日韩人妻无码精品久 | 国产精品国三级国产av视色 | 亚洲春色在线视频 | 亚洲人成网站观看在线播放 | 成人无码 | 精品国产一区二区三区av性色 | 91抖阴短视频成人版 | 欧美成人aa久久狼窝五月丁香 | 精品国产aⅴ无码一区二区 精品国产aⅴ无码一区二区蜜桃 | 无码人妻一区二区三区免费 | 亚洲欧美综合 | 日韩a毛片免费观看 | 狠狠色噜噜狠狠 | 精品三级av无码一区 | 美女一区二区十八岁毛片在线观看 | 爽人人爽人人片av东京热 | 亚洲精品一级无码中文字幕 | 日韩无码第二页 | 中文国产成人精品久久app | 亚洲国内精品自在线影视 | 欧美大片欧美激情性色a∨在线 | av不卡在线免费看 | 国产爆乳美女娇喘呻吟在线观看 | 夜夜操网站夜夜操尤物 | 免费福利网站在线观看 | 麻豆国产av超爽剧情系列 | 日本精品久久久久精品三级 | 亚洲国内精品三级在线观看 | 日产无码久久久久久精品 | 欧美成人一区二区三区 | 精品一区二区三区在线观看视频 | 91精品一区二 | 午夜专区三级无码 | 日本精品a在线观看 |